NCT07020520 (ENDURE1) is a NA clinical trial of Optilume in Ureteral Stricture, sponsored by Urotronic Inc..

Who is sponsoring NCT07020520?

NCT07020520 is sponsored by Urotronic Inc..

What drugs are being tested in NCT07020520?

Interventions in NCT07020520: Optilume.

What condition does NCT07020520 study?

NCT07020520 studies Ureteral Stricture.

Is NCT07020520 still recruiting?

NCT07020520 is currently recruiting now. Last updated 9 March 2026.

Last reviewed 2026-03-09 · How we verify

NCT07020520: ENDURE1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures

Recruiting now NA Last updated 9 March 2026

What this trial tests

NA trial testing Optilume in Ureteral Stricture in 60 participants. Currently enrolling.

Timeline

1 October 2025

Primary endpoint
28 February 2027

30 July 2031

Quick facts

Lead sponsor	Urotronic Inc.
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 October 2025
Primary completion	28 February 2027
Estimated completion	30 July 2031
Sites	7 locations across United States

Drugs / interventions tested

Optilume

Conditions studied

Ureteral Stricture — all drugs for Ureteral Stricture →

Sponsor

Urotronic Inc. — full company profile →

Who can join

18 and older, any sex, with Ureteral Stricture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this clinical investigation is to assess the safety and feasibility of the Optilume DCB for treatment of ureteric strictures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Paclitaxel-coated balloon adjunct for benign ureteral and ureteroenteric strictures: a narrative review and translational proposal for enhanced endourological patency.
Diéguez-Álvarez L, Panach-Navarrete J, Martínez-Jabaloyas JM. · · 2026 · PMID 42164385 · DOI 10.21037/tau-2025-1-921

Verify or expand the search:

Other recruiting trials for Ureteral Stricture

Currently open trials in the same condition.

NCT06983067 — Application of the Sentire C1000 for Ureteral Stricture Repair · recruiting

Other Urotronic Inc. trials

Trials by the same sponsor.

NCT06560476 — OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH · recruiting
NCT06312722 — Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study · NA · recruiting
NCT05383274 — Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters · Phase 4 · recruiting
NCT03851952 — Re-Establishing Flow Via Drug Coated Balloon for the Treatment of Urethral Stricture Disease - Registry Study · NA · withdrawn
NCT03423979 — Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07020520 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Urotronic Inc.
Last refreshed: 9 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07020520.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing